Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients. (9th June 2018)

• Record Type: Journal Article
• Authors: Höner zu Siederdissen, Christoph; Hui, Aric Josun; Sukeepaisarnjaroen, Wattana; Tangkijvanich, Pisit; Su, Wei Wen; Nieto, Gerardo Enrique Guillén; Gineste, Paul; Nitcheu, Josianne; Crabé, Sandrine; Stepien, Sandrine; Manns, Michael P; Trépo, Christian; Wedemeyer, Heiner; Cornberg, Markus
• Is Part Of: Journal of infectious diseases. Volume 218:Number 9(2018)
• Page Start: 1480
• Page End: 1484
• Publication Date: 2018-06-09
• Subjects: Virological relapse -- nucleos(t)ide discontinuation -- tenofovir -- entecavir -- HBeAg negative hepatitis B virus infection; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiy350
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract: Stopping long-term nucleos(t)ide analogue therapy increases hepatitis B virus (HBV) surface antigen (HBsAg) loss rates in HBV e antigen (HBeAg)–negative patients. Viral rebound may induce immune responses facilitating functional cure. We analyzed which factors are associated with timing of virological relapse in 220 Asian HBeAg-negative patients from the prospective ABX203 vaccine study. Unexpectedly, only the type of antiviral therapy was significantly associated with early virological relapse, defined as an HBV DNA load of >2000 IU/mL until week 12, and relapse occurred earlier in patients treated with tenofovir versus those treated with entecavir (median time, 6 vs 24 weeks; P < .0001). This should be considered for future trials and monitoring of patients after treatment discontinuation.